News / Press Release

Where Do Cancer Clinical Trials Take Place?

October 21, 2016

Conducted in hospitals, veterans’ medical centers, university hospitals, medical clinics, cancer centers or physicians’ offices, cancer clinical trials test drugs, blood products, medical devices, biologics and other therapies that have the potential for treating cancer. Locations of cancer clinical trials may depend on whether unique resources are necessary for conducting the trial as rigorously as possible. In addition, location may be influenced by the number of subjects required and/or how much interest the institution or individual shows in having a clinical trial take place at their location.

Examples of the various places where cancer clinical trials conducted can be found on the ClinicalTrials.gov website. Some of the locations currently accepting participants include the University of Texas MD Anderson Cancer Center in Houston, TX, the Sun Yat-sen University Cancer Center in Guangzhou, Guangdong, China and the Memorial Sloan Kettering Cancer Center in NYC.

Clinical Trial Locations and Protocols

Establishing a location for a completing a cancer clinical trial involves developing protocols for ensuring the location is optimized for research quality and validity. Pre-assessment of possible site locations requires approval from regulatory agencies as well as ethics committees. Trial locations should be equipped with personnel and devices pertinent and necessary to recording investigational results. In addition, trial sites should not pose any health risks to subjects participating in the trial.

Studies reveal that inferior trial qualities stemming from wrong location choices or lack of adherence to protocols can distort outcomes of trials. Although site selection is typically not addressed as seriously as other aspects of clinical trials, it does demand adequate attention by sponsors to guarantee the trial meets or exceeds components supporting the study's success. Location selection should also consider population/demographic targets of a proposed clinical trial to ensure validity of results.

Any new cancer treatment included in a clinical trial must be thoroughly evaluated to determine if the treatment poses a health risk to human subjects. Research regarding potential health risks may be performed at the site of the proposed clinical cancer trial or at another location. Cancer therapies producing excellent safety profiles and presenting promising results may then move into the clinical trial phase using human volunteers.

If you have further questions about locations of cancer clinical trials, please contact us today.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: